SGLT2 inhibitors and the kidney: Effects and mechanisms

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 12, Issue 6, 2018, Pages 1117-1123

  Tsimihodimos, V ^a   Filippatos, T D ^b   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Acute kidney injury; Ketones; Key words; Kidney; Nephroprotection; Sodium glucose cotransporter 2

Indexed keywords

GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ACUTE KIDNEY FAILURE; ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; DISEASE PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; METABOLISM; OXYGENATION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; URINARY TRACT INFECTION; CHRONIC KIDNEY FAILURE; DRUG EFFECT; DRUG THERAPY; KIDNEY; PHARMACOLOGY;

HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85048858085     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2018.06.003     Document Type: Review

References (82)

1. Tsimihodimos, V., Panagiotopoulou, T., Tzavella, E., Elisaf, M., Clinical pharmacology of sodium glucose cotransporter 2 inhibitors. Hellenic J Atherosclerosis, 8, 2017.
2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
4. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
5. Cherney, D.Z.I., Zinman, B., Inzucchi, S.E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
6. Mahaffey, K.W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation 137 (2018), 323–334.
7. Wanner, C., Lachin, J.M., Inzucchi, S.E., Fitchett, D., Mattheus, M., George, J., et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
8. Petrykiv, S., Sjostrom, C.D., Greasley, P.J., Xu, J., Persson, F., Heerspink, H.J.L., Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12 (2017), 751–759.
9. Dekkers, C.C.J., Wheeler, D.C., Sjostrom, C.D., Stefansson, B.V., Cain, V., Heerspink, H.J.L., Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transplant, 2018 Epub ahead of print.
10. Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meininger, G., Perkovic, V., Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
11. Zhang, X.L., Zhu, Q.Q., Chen, Y.H., Li, X.L., Chen, F., Huang, J.A., et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc, 7, 2018.
12. Xu, L., Li, Y., Lang, J., Xia, P., Zhao, X., Wang, L., et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ, 5, 2017, e3405.
13. Muskiet, M.H.A., Heerspink, H.J.L., van Raalte, D.H., SGLT2 inhibition: a new era in renoprotective medicine?. Lancet Diabetes Endocrinol 5 (2017), 569–571.
14. Pecoits-Filho, R., Perkovic, V., Are SGLT2 inhibitors ready for prime time for CKD?. Clin J Am Soc Nephrol 13 (2018), 318–320.
15. Tsimihodimos, V., Filippatos, T.D., Filippas-Ntekouan, S., Elisaf, M., Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. Curr Vasc Pharmacol 15 (2017), 96–102.
16. Ferrannini, E., Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26 (2017), 27–38.
17. Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
18. Guthrie, R.M., Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 125 (2013), 21–32.
19. Basile, J.N., The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Compl. 27 (2013), 280–286.
20. Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V.T., Hohenstein, B., et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307 (2014), F317–25.
21. Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014 e100777.
22. Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K.A., Koepsell, H., et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304 (2013), F156–67.
23. Vallon, V., Gerasimova, M., Rose, M.A., Masuda, T., Satriano, J., Mayoux, E., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–204.
24. Maeda, S., Matsui, T., Takeuchi, M., Yamagishi, S., Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 29 (2013), 406–412.
25. Panchapakesan, U., Pegg, K., Gross, S., Komala, M.G., Mudaliar, H., Forbes, J., et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy?. PLoS One, 8, 2013 e54442.
26. van Bommel, E.J., Muskiet, M.H., Tonneijck, L., Kramer, M.H., Nieuwdorp, M., van Raalte, D.H., SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12 (2017), 700–710.
27. Vallon, V., Thomson, S.C., Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60 (2017), 215–225.
28. Wanner, C., EMPA-REG OUTCOME: the nephrologist's point of view. Am J Med 130 (2017), S63–S72.
29. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
30. Skrtic, M., Yang, G.K., Perkins, B.A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57 (2014), 2599–2602.
31. Heerspink, H.J., Kropelin, T.F., Hoekman, J., de Zeeuw, D., Reducing albuminuria as surrogate endpoint C. Drug-induced reduction in Albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
32. Filippatos, T.D., Tsimihodimos, V., Elisaf, M.S., Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother 17 (2016), 1581–1583.
33. Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
34. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
35. Cushman, W.C., Evans, G.W., Byington, R.P., Goff, D.C. Jr., Grimm, R.H. Jr., Cutler, J.A., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
36. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
37. Tsimihodimos, V., Filippatos, T.D., Elisaf, M.S., Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opin Drug Metab Toxicol 13 (2017), 399–408.
38. Look, A.R.G., Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2 (2014), 801–809.
39. Packer, M., Do Sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab 20:6 (2018), 1361–1366.
40. Timothy Garvey, W., Van Gaal, L., Leiter, L.A., Vijapurkar, U., List, J., Cuddihy, R., et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism, 2018 Epub ahead of print.
41. Johnson, R.J., Nakagawa, T., Jalal, D., Sanchez-Lozada, L.G., Kang, D.H., Ritz, E., Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transpl 28 (2013), 2221–2228.
42. Richette, P., Perez-Ruiz, F., Doherty, M., Jansen, T.L., Nuki, G., Pascual, E., et al. Improving cardiovascular and renal outcomes in gout: what should we target?. Nat Rev Rheumatol 10 (2014), 654–661.
43. Bankir, L., Bouby, N., Blondeau, B., Crambert, G., Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am J Physiol Renal Physiol 311 (2016), F469–86.
44. Bankir, L., Roussel, R., Bouby, N., Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Renal Physiol 309 (2015), F2–23.
45. Ellison, D.H., Felker, G.M., Diuretic treatment in heart failure. N Engl J Med 377 (2017), 1964–1975.
46. Packer, M., Anker, S.D., Butler, J., Filippatos, G., Zannad, F., Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2 (2017), 1025–1029.
47. Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
48. Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci, 18, 2017.
49. Korner, A., Eklof, A.C., Celsi, G., Aperia, A., Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43 (1994), 629–633.
50. Fine, L.G., Norman, J.T., Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74 (2008), 867–872.
51. Layton, A.T., Vallon, V., SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol, 2018.
52. Layton, A.T., Vallon, V., Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases. Acta Physiol (Oxf), 222, 2018 e13050.
53. Haase, V.H., Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291 (2006), F271–81.
54. Chang, Y.K., Choi, H., Jeong, J.Y., Na, K.R., Lee, K.W., Lim, B.J., et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 11, 2016 e0158810.
55. Baker, W.L., Smyth, L.R., Riche, D.M., Bourret, E.M., Chamberlin, K.W., White, W.B., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275 e9.
56. Aizawa, K., Takeda, S., Tashiro, Y., Yorozu, K., Hirata, M., Kanada, H., et al. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol 36 (2012), 419–426.
57. Serizawa, K., Yogo, K., Tashiro, Y., Aizawa, K., Kawasaki, R., Hirata, M., et al. Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats. Eur J Pharmacol 767 (2015), 10–16.
58. Eren, Z., Gunal, M.Y., Ari, E., Coban, J., Cakalagaoglu, F., Caglayan, B., et al. Pleiotropic and renoprotective effects of erythropoietin beta on experimental diabetic nephropathy model. Nephron 132 (2016), 292–300.
59. Tsuruya, K., Yoshida, H., Suehiro, T., Fujisaki, K., Masutani, K., Kitazono, T., Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Ren Fail 38 (2016), 390–396.
60. Muskiet, M.H., van Raalte, D.H., van Bommel, E.J., Smits, M.M., Tonneijck, L., Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
61. Padda, R.S., Shi, Y., Lo, C.S., Zhang, S.L., Chan, J.S., Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes?. J Diabetes Metab, 6, 2015.
62. Rodrigues Prestes, T.R., Rocha, N.P., Miranda, A.S., Teixeira, A.L., Simoes, E.S.A.C., The anti-inflammatory potential of ACE2/Angiotensin-(1-7)/Mas receptor axis: evidence from basic and clinical research. Curr Drug Targets 18 (2017), 1301–1313.
63. Shi, Y., Lo, C.S., Padda, R., Abdo, S., Chenier, I., Filep, J.G., et al. Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. Clin Sci (Lond) 128 (2015), 649–663.
64. Sano, M., A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71 (2018), 471–476.
65. Matthews, V.B., Elliot, R.H., Rudnicka, C., Hricova, J., Herat, L., Schlaich, M.P., Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 35 (2017), 2059–2068.
66. Mishima, E., Fukuda, S., Kanemitsu, Y., Saigusa, D., Mukawa, C., Asaji, K., et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am J Physiol Renal Physiol, 2017 ajprenal003142017.
67. Wang, X.X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292 (2017), 5335–5348.
68. Filippas-Ntekouan, S., Filippatos, T.D., Elisaf, M.S., SGLT2 inhibitors: are they safe?. Postgrad Med 130 (2018), 72–82.
69. Perlman, A., Heyman, S.N., Matok, I., Stokar, J., Muszkat, M., Szalat, A., Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 27 (2017), 1108–1113.
70. Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 1106–1115.
71. Nadkarni, G.N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., et al. Acute kidney injury in patients on sglt2 inhibitors: a propensity-matched analysis. Diabetes Care 40 (2017), 1479–1485.
72. Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J, 2016, 10.1093/eurheartj/ehw110.
73. Szalat, A., Perlman, A., Muszkat, M., Khamaisi, M., Abassi, Z., Heyman, S.N., Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41 (2018), 239–252.
74. Hahn, K., Ejaz, A.A., Kanbay, M., Lanaspa, M.A., Johnson, R.J., Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12 (2016), 711–712.
75. O'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzen, S., Palm, F., Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309 (2015), F227–34.
76. Saly, D.L., Perazella, M.A., Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol 313 (2017), F951–F954.
77. Hahn, K., Kanbay, M., Lanaspa, M.A., Johnson, R.J., Ejaz, A.A., Serum uric acid and acute kidney injury: a mini review. J Adv Res 8 (2017), 529–536.
78. Bjornstad, P., Lanaspa, M.A., Ishimoto, T., Kosugi, T., Kume, S., Jalal, D., et al. Fructose and uric acid in diabetic nephropathy. Diabetologia 58 (2015), 1993–2002.
79. Kitamura, H., Yamauchi, A., Sugiura, T., Matsuoka, Y., Horio, M., Tohyama, M., et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int 53 (1998), 146–153.
80. Filippatos, T.D., Tsimihodimos, V., Liamis, G., Elisaf, M.S., SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr 12 (2018), 59–63.
81. Jia, Y., He, J., Wang, L., Su, L., Lei, L., Huang, W., et al. Dapagliflozin aggravates renal injury via promoting gluconeogenesis in db/db mice. Cell Physiol Biochem 45 (2018), 1747–1758.
82. Secker, P.F., Beneke, S., Schlichenmaier, N., Delp, J., Gutbier, S., Leist, M., et al. Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis, 9, 2018, 226.